March 29, 2017: Vertex is closing a research facility in Canada, while at the same time consolidating R&D operations down to three operations.
March 29, 2017: The FDA approved Genentech's Ocrevus (ocrelizumab) for MS. It is now the first and only drug approved for both relapsing and primary progressive forms of MS.
March 29, 2017: According to a Form 13 filing with the SEC, Celgene on March 24, 2017 acquired 75,568 shares of Juno for $22.3882 per share, at an aggregate purchase price of $1.69M.
March 29, 2017: President Trump is looking for some extra cash this year. And to get it he’s ready to start slashing NIH funding now, rather than wait until the next budget year gets started.